Repligen Corporation (RGEN)
| Bid | 140.52 |
| Market Cap | 8.15B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.03 |
| PE Ratio (ttm) | -4850 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 149.84 |
| Volume | 411,161 |
| Avg. Volume (20D) | 530,250 |
| Open | 147.29 |
| Previous Close | 146.92 |
| Day's Range | 143.89 - 148.70 |
| 52-Week Range | 113.50 - 207.87 |
| Beta | undefined |
About RGEN
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used i...
Analyst Forecast
According to 12 analyst ratings, the average rating for RGEN stock is "Buy." The 12-month stock price forecast is $180, which is an increase of 23.71% from the latest price.
Next Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago · https://thefly.com
Repligen price target lowered to $180 from $240 at H.C. WainwrightH.C. Wainwright lowered the firm's price target on Repligen to $180 from $240 and keeps a Buy rating on the shares. The firm says the company could generate solid top- and bottom-line growth in the co...
